Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, according to Benzinga Pro.Revenues increased 11% year-over-year in U.S. dollars or 9% in local currency.The increase was mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) and from higher revenues from key innovative products, par ...